Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Treatment related factors and inhibitor development in children with severe haemophilia A.

Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA; Paediatric Working Party of UKHCDO..

Haemophilia. 2011 Mar;17(2):282-7. doi: 10.1111/j.1365-2516.2010.02422.x. Epub 2010 Nov 11.

PMID:
21070501
2.

Immune response to FVIII in hemophilia A: an overview of risk factors.

Ghosh K, Shetty S.

Clin Rev Allergy Immunol. 2009 Oct;37(2):58-66. doi: 10.1007/s12016-009-8118-1. Review.

PMID:
19148784
3.

Inhibitors: our greatest challenge. Can we minimize the incidence?

Kruse-Jarres R.

Haemophilia. 2013 Jan;19 Suppl 1:2-7. doi: 10.1111/hae.12049. Review.

PMID:
23278993
4.

Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.

Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G.

Haemophilia. 2010 Jan;16 Suppl 1:13-9. doi: 10.1111/j.1365-2516.2009.02175.x. Review.

PMID:
20059564
5.

The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.

Gouw SC, van den Berg HM.

Semin Thromb Hemost. 2009 Nov;35(8):723-34. doi: 10.1055/s-0029-1245105. Epub 2010 Feb 18. Review.

PMID:
20169509
6.

Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.

Mancuso ME, Graca L, Auerswald G, Santagostino E.

Haemophilia. 2009 Jan;15 Suppl 1:8-14. doi: 10.1111/j.1365-2516.2008.01947.x. Review.

PMID:
19125935
7.

The epidemiology of factor VIII inhibitors.

Hay CR.

Haemophilia. 2006 Dec;12 Suppl 6:23-8; discussion 28-9. Review.

PMID:
17123390
8.

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD.

J Thromb Haemost. 2003 Jun;1(6):1228-36. Review.

9.

Assessing risk factors: prevention of inhibitors in haemophilia.

Chambost H.

Haemophilia. 2010 Mar;16 Suppl 2:10-5. doi: 10.1111/j.1365-2516.2009.02197.x. Review.

PMID:
20132333
10.

Inhibitor development in correlation to factor VIII genotypes.

Oldenburg J, El-Maarri O, Schwaab R.

Haemophilia. 2002 Mar;8 Suppl 2:23-9. Review.

PMID:
11966849
11.

Treatment of patients with haemophilia and inhibitory antibodies.

Giangrande PL.

Indian J Pediatr. 2003 Aug;70(8):655-9. Review.

PMID:
14510087
12.

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.

Lee CA, Lillicrap D, Astermark J.

Semin Thromb Hemost. 2006 Jun;32 Suppl 2:10-4. Review.

PMID:
16804830
13.

Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.

van Helden PM, Van Haren SD, Fijnvandraat K, van den Berg HM, Voorberg J.

Haemophilia. 2010 May;16(102):35-43. doi: 10.1111/j.1365-2516.2010.02215.x. Review.

PMID:
20536984
14.

Genetic risk factors for inhibitors to factors VIII and IX.

Oldenburg J, Pavlova A.

Haemophilia. 2006 Dec;12 Suppl 6:15-22. Review.

PMID:
17123389
15.

Characteristics of inhibitors in mild/moderate haemophilia A.

Peerlinck K, Jacquemin M.

Haemophilia. 2006 Dec;12 Suppl 6:43-7. Review.

PMID:
17123393
16.
17.
18.

Surgery and inhibitor development in hemophilia A: a systematic review.

Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K.

J Thromb Haemost. 2011 Oct;9(10):1948-58. doi: 10.1111/j.1538-7836.2011.04467.x. Review.

19.

Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.

Astermark J.

Haemophilia. 2006 Dec;12 Suppl 6:8-13; discussion 13-4. Review.

PMID:
17123388
20.

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.

Ettingshausen CE, Kreuz W.

Haemophilia. 2006 Dec;12 Suppl 6:102-6. Review.

PMID:
17123402

Supplemental Content

Support Center